Dr. Puja Srivastava discussed the concept of JAK inhibitor utility in the management of autoimmune diseases. Activation of the JAK-STAT Signal transduction pathway is a critical event in AI disorder pathogenesis. It has good efficacy in trials and clinics. Potential safety concerns can be mitigated by recommended screening and monitoring tests. It is relatively contraindicated for pregnancy and breastfeeding women, patients with recurrent infections, increased risk of DVD/PE, and diverticulitis.